Correlation between Ki67 and Histological Grade in Breast Cancer Patients Treated with Preoperative Chemotherapy |
Petric, Militza
(Department of Oncologic and Maxillofacial Surgery, School of Medicine, Pontificia Universidad Catolica de Chile)
Martinez, Santiago (Pathology Department, School of Medicine, Pontificia Universidad Catolica de Chile) Acevedo, Francisco (Haematology & Oncology Department, Cancer Programme, School of Medicine, Pontificia Universidad Catolica de Chile) Oddo, David (Pathology Department, School of Medicine, Pontificia Universidad Catolica de Chile) Artigas, Rocio (Haematology & Oncology Department, Cancer Programme, School of Medicine, Pontificia Universidad Catolica de Chile) Camus, Mauricio (Department of Oncologic and Maxillofacial Surgery, School of Medicine, Pontificia Universidad Catolica de Chile) Sanchez, Cesar (Haematology & Oncology Department, Cancer Programme, School of Medicine, Pontificia Universidad Catolica de Chile) |
1 | Acevedo F, Herrera ME, Madrid J, Sanchez C (2013). Neoadyuvant endocrine therapy in breast cancer. Revista Medica de Chile, 141, 367-74. DOI |
2 | Berry DA, Cronin KA, Plevritis SK, et al (2005). Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl J Med, 353, 1784-92. DOI |
3 | Burstein HJ, Piccart-Gebhart MJ, Perez EA (2012). Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol, 30, 2179-82. DOI |
4 | Cuzick J, Dowsett M, Pineda S, et al (2011). Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol, 29, 4273-78. DOI |
5 | De Azambuja E, Cardoso F, De Castro G Jr (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer, 96, 1504-13. DOI |
6 | Elston CW, Ellis IO (2002). Pathological prognostic factors in breast cancer. i. the value of histological grade in breast cancer: experience from a large study with long-term followup. Histopathology, 41, 154-61. DOI |
7 | Galea MH, Blamey RW, Elston CE, Ellis IO (1992). The nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat, 22, 207-19. DOI |
8 | Goldhirsch A, Winer EP, Coates AS (2013). Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol, 24, 2206-23. DOI ScienceOn |
9 | Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the st. gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol, 22, 1736-47. DOI ScienceOn |
10 | Jin SH, Kim SH, Kang BJ, et al (2014). Breast cancer recurrence according to molecular subtype. Asian Pac J Cancer Prev, 15, 5539-44. DOI |
11 | Khokher S, Qureshi MU, Mahmood S, Nagi AH (2013). Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer. Asian Pac J Cancer Prev, 14, 3223-28. DOI ScienceOn |
12 | Kilickap S, Kaya Y, Yucel B, et al (2014). Higher ki67 expression is associated with unfavorable prognostic factors and shorter survival in breast cancer. Asian Pac J Cancer Prev, 15, 1381-85. DOI |
13 | Kumaki N, Umemura S, Tang X, et al (2011). Alteration of immunohistochemical biomarkers between pre-and postchemotherapy: hormone receptors, HER2 and Ki-67. Breast Cancer, 18, 98-102. DOI |
14 | Rinat Y, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 11, 174-83. DOI |
15 | Paik S, Shak S, Tang G, et al (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England J Med, 351. |
16 | Pathmanathan N, Balleine RL (2013). Ki67 and proliferation in breast cancer. J Clin Pathol, 66, 512-16. DOI |
17 | Reis-Filho J, Pusztai L (2011). Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet, 378, 1812-23. DOI ScienceOn |
18 | Saroona H, Hashmi AA, Khurshid A, et al (2013). Ki67 index in breast cancer: correlation with other prognostic markers and potential in Pakistani patients. Asian Pac J Cancer Prev, 14, 4353-58. DOI |
19 | Stumpp J, Dietl J, Simon W, Geppert M (1992). Growth fraction in breast carcinoma determined by Ki-67 immunostaining: correlation with pathological and clinical variables. Gynecol Obstet Invest, 33, 47-50. DOI |
20 | Gong T, Shak S, Paik S, et al (2011). Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat, 127, 133-42. DOI |
21 | Tanriverdi O, Meydan N, Barutca S (2014). Reconsideration of clinical and histopathological prognostic factors in breast cancer patients: A single center experience. Asian Pac J Cancer Prev, 15, 807-12. DOI |
22 | The Cancer Genome Atlas Research Network (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490, 61-70. DOI ScienceOn |
23 | Yoo C, Ahn J-H, Jung KH, et al (2012). Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. J Breast Cancer, 15, 203-10. DOI ScienceOn |
24 | Viale Giuseppe, Anita Giobbie-Hurder, Meredith M Regan, et al (2008). Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from breast international group trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol, 26, 5569-75. DOI |